Epoetin Delta

Summary

Epoetin Delta (CHEMBL2109093) is an approved protein; indicated across 2 conditions including chronic kidney disease and anemia.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Protein
• Indications: 2 conditions
• Clinical trials: 2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2109093
Name	Epoetin Delta
Type	Protein
Max phase	4

Also known as: Dynepo, Epoetin delta, Epoetina delta, Epoetine delta, GA-EPO, HMR-4396, HMR4396, EPOETIN DELTA

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 approved indications. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
chronic kidney disease	4	MONDO:0005300	EFO:0003884
anemia	4	MONDO:0002280	EFO:0004272

Clinical trials

Total trials: 2.

Phase distribution

Phase	Trials
PHASE4	1
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00514813	PHASE4	TERMINATED	Dynepo Long-Term Safety Study
NCT00450333	PHASE3	TERMINATED	Dynepo Infrequent Dosing Study

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).